MedTrace Logo

Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC Patients

NCT01415674 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2022-02-02

No results posted yet for this study

Summary

The purpose of this study is to identify predictive and pharmacodynamic biomarkers of activity and efficacy of pre-operative Afatinib (BIBW2992) in untreated non-metastatic head and neck squamous cell carcinoma patients

Conditions

  • Carcinoma, Squamous Cell of Head and Neck

Interventions

DRUG

Afatinib

Afatinib 40mg per os daily for 14 to 28 days, depending on the date of the surgery

Sponsors & Collaborators

  • UNICANCER

    lead OTHER

Principal Investigators

  • Christophe Le Tourneau · Institut Curie Paris

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01415674 on ClinicalTrials.gov